A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy

NCT ID: NCT04252846

Last Updated: 2023-02-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

191 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-20

Study Completion Date

2023-01-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this study is to assess the retention rate of perampanel as a reliable proxy for overall effectiveness and tolerability in participants aged at least 12 years who are prescribed perampanel (for partial onset seizures \[POS\] with or without secondary generalization \[SG\] or for primary generalized tonic-clonic seizures \[PGTCS\] associated with idiopathic generalized epilepsy \[IGE\] as first adjunctive to antiepileptic drug (AED) monotherapy as part of their routine clinical care.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Idiopathic Generalized Epilepsy Partial Onset Seizures Generalised Tonic-Clonic Seizures

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Perampanel

Participants with a diagnosis of epilepsy (POS with or without SG or PGTCS associated with IGE) will initiate treatment with perampanel as first adjunctive treatment as per the clinical judgment of the treating physician as part of routine clinical care. All participants will be observed prospectively for up to 12 months after initiation of perampanel treatment.

Perampanel

Intervention Type DRUG

Perampanel oral tablets or oral suspension.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Perampanel

Perampanel oral tablets or oral suspension.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fycompa

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosis of epilepsy
2. History of POS with or without SG or PGTCS associated with IGE
3. Documented POS with or without SG or PGTCS associated with IGE, within the past 12 months
4. Previously treated with 1 or 2 AEDs as monotherapy
5. At least 4 weeks' seizure diary data, or sufficient clinical detail to calculate baseline seizure frequency

Exclusion Criteria

1. Episode(s) of status epilepticus within the past 6 months before Screening
2. Previously treated with 2 or more AEDs in combination (other than during cross-titration between AED monotherapies)
3. Previous or current use of perampanel

Note: Retrospective inclusions will be allowed but only if the time between the initiation of perampanel treatment and the inclusion does not exceed 7 calendar days
4. Hypersensitivity to perampanel or any of the excipients
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eisai Limited

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sydvestjysk Sygehus Esbjerg

Esbjerg, Region Syddanmark, Denmark

Site Status

Hôpital Pontchaillou

Rennes, Ille-et-Vilaine, France

Site Status

Hôpital Roger Salengro

Lille, Nord, France

Site Status

Centre de consultations Saint-Jean Bâtiment A

Cagnes-sur-Mer, , France

Site Status

Hopitaux de La Timone

Marseille, , France

Site Status

Hôpital Robert Debré

Paris, , France

Site Status

Centre hospitalier de Pau

Pau, , France

Site Status

Centre Hospitalier Universitaire de Toulouse

Toulouse, , France

Site Status

CHRU Bretonneau

Tours, , France

Site Status

Eisai Trial Site #2

Berlin, , Germany

Site Status

Eisai Trial Site #1

Ulm, , Germany

Site Status

AORN A Cardarelli

Naples, Campania, Italy

Site Status

Azienda Sanitaria Universitaria Integrata di Udine - PO Universitario Santa Maria della Misericordia

Udine, Friuli Venezia Giulia, Italy

Site Status

Fondazione PTV Policlinico Tor Vergata

Rome, Lazio, Italy

Site Status

ASST Santi Paolo e Carlo - Azienda Universitaria-Polo Universitario San Paolo

Milan, Lombardy, Italy

Site Status

Ospedale di Merano

Merano, Trentino-Alto Adige, Italy

Site Status

Ospedale Santa Maria Della Misericordia Di Perugia

Perugia, Umbria, Italy

Site Status

Ospedale Policlinico San Martino

Genova, , Italy

Site Status

Azienda Ospedaliera Universitaria Federico II

Napoli, , Italy

Site Status

Policlinico Universitario Campus Biomedico Di Roma

Roma, , Italy

Site Status

Centro Hospitalar E Universitário de Coimbra EPE

Coimbra, , Portugal

Site Status

Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria

Lisbon, , Portugal

Site Status

Centro Hospitalar de São João, E.P.E.

Porto, , Portugal

Site Status

Krasnoyarsk State Medical University n.a. V.F. Voyno-Ysenetskiy

Krasnoyarsk, , Russia

Site Status

City Clinical Hospital #1 n.a. N.I.Pirogov

Moscow, , Russia

Site Status

Moscow State Medical Stomatological University n.a. A.I. Evdokimov

Moscow, , Russia

Site Status

Russian National Research Medical University n.a. N.I.Pirogov

Moscow, , Russia

Site Status

City Neurology Center Sibneuromed LLC

Novosibirsk, , Russia

Site Status

Regional Treatment and Rehabilitation Center

Tyumen, , Russia

Site Status

CHUVI - H.U. Alvaro Cunqueiro

Vigo, Pontevedra, Spain

Site Status

Hospital Universitari Sagrat Cor Quironsalud

Barcelona, , Spain

Site Status

Hospital Universitario Virgen de Las Nieves

Granada, , Spain

Site Status

Hospital Regional Universitario de Malaga - Hospital General

Málaga, , Spain

Site Status

Hospital Universitario de Donostia

San Sebastián, , Spain

Site Status

Hospital Universitario Virgen Macarena

Seville, , Spain

Site Status

Hospital Clinico Universitario de Valladolid

Valladolid, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark France Germany Italy Portugal Russia Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

E2007-M044-512

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.